Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014

Michael W. Weiner, Dallas P. Veitch, Paul S. Aisen, Laurel A. Beckett, Nigel J. Cairns, Jesse Cedarbaum, Michael C. Donohue, Robert C. Green, Danielle Harvey, Clifford R. Jack, William Jagust, John C. Morris, Ronald C. Petersen, Andrew J. Saykin, Leslie Shaw, Paul M. Thompson, Arthur W. Toga, John Q. Trojanowski

Research output: Contribution to journalReview article

96 Scopus citations

Abstract

Introduction The Alzheimer's Disease Neuroimaging Initiative (ADNI) was established in 2004 to facilitate the development of effective treatments for Alzheimer's disease (AD) by validating biomarkers for AD clinical trials. Methods We searched for ADNI publications using established methods. Results ADNI has (1) developed standardized biomarkers for use in clinical trial subject selection and as surrogate outcome measures; (2) standardized protocols for use across multiple centers; (3) initiated worldwide ADNI; (4) inspired initiatives investigating traumatic brain injury and post-traumatic stress disorder in military populations, and depression, respectively, as an AD risk factor; (5) acted as a data-sharing model; (6) generated data used in over 600 publications, leading to the identification of novel AD risk alleles, and an understanding of the relationship between biomarkers and AD progression; and (7) inspired other public-private partnerships developing biomarkers for Parkinson's disease and multiple sclerosis. Discussion ADNI has made myriad impacts in its first decade. A competitive renewal of the project in 2015 would see the use of newly developed tau imaging ligands, and the continued development of recruitment strategies and outcome measures for clinical trials.

Original languageEnglish (US)
Pages (from-to)865-884
Number of pages20
JournalAlzheimer's and Dementia
Volume11
Issue number7
DOIs
StatePublished - Jul 1 2015
Externally publishedYes

Keywords

  • AD biomarker signature
  • Alzheimer's disease
  • Amyloid phenotyping
  • Clinical trial biomarkers
  • Data-sharing
  • Tau imaging
  • Worldwide ADNI

ASJC Scopus subject areas

  • Clinical Neurology
  • Developmental Neuroscience
  • Cellular and Molecular Neuroscience
  • Psychiatry and Mental health
  • Geriatrics and Gerontology
  • Epidemiology
  • Health Policy

Fingerprint Dive into the research topics of 'Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014'. Together they form a unique fingerprint.

  • Cite this

    Weiner, M. W., Veitch, D. P., Aisen, P. S., Beckett, L. A., Cairns, N. J., Cedarbaum, J., Donohue, M. C., Green, R. C., Harvey, D., Jack, C. R., Jagust, W., Morris, J. C., Petersen, R. C., Saykin, A. J., Shaw, L., Thompson, P. M., Toga, A. W., & Trojanowski, J. Q. (2015). Impact of the Alzheimer's Disease Neuroimaging Initiative, 2004 to 2014. Alzheimer's and Dementia, 11(7), 865-884. https://doi.org/10.1016/j.jalz.2015.04.005